Cargando…

The intramembrane protease Sppl2a is required for B cell and DC development and survival via cleavage of the invariant chain

B cell development requires tight regulation to allow for the generation of a diverse repertoire while preventing the development of autoreactive cells. We report, using N-ethyl-N-nitrosourea (ENU)–induced mutagenesis, the identification of a mutant mouse (chompB) with a block in early B cell develo...

Descripción completa

Detalles Bibliográficos
Autores principales: Beisner, Daniel R., Langerak, Petra, Parker, Albert E., Dahlberg, Carol, Otero, Francella J., Sutton, Sue E., Poirot, Laurent, Barnes, Whitney, Young, Michael A., Niessen, Sherry, Wiltshire, Tim, Bodendorf, Ursula, Martoglio, Bruno, Cravatt, Benjamin, Cooke, Michael P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549714/
https://www.ncbi.nlm.nih.gov/pubmed/23267013
http://dx.doi.org/10.1084/jem.20121072
Descripción
Sumario:B cell development requires tight regulation to allow for the generation of a diverse repertoire while preventing the development of autoreactive cells. We report, using N-ethyl-N-nitrosourea (ENU)–induced mutagenesis, the identification of a mutant mouse (chompB) with a block in early B cell development. The blockade occurs after the transitional 1 (T1) stage and leads to a decrease in mature B cell subsets and deficits in T cell–dependent antibody responses. Additionally, chompB mice have decreases in myeloid dendritic cells (DCs). The mutation was mapped to the intramembrane protease signal peptide peptidase-like 2a (Sppl2a), a gene not previously implicated in immune cell development. Proteomic analysis identified the invariant chain (CD74) as a key substrate of Sppl2a and suggests that regulated intramembrane proteolysis of CD74 by Sppl2a contributes to B cell and DC survival. Moreover, these data suggest that modulation of Sppl2a may be a useful therapeutic strategy for treatment of B cell dependent autoimmune disorders.